No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KBR KBR Inc
- 62.130
- -0.090-0.14%
Close Apr 18 16:00 ET
8.37BMarket Cap-31698P/E (TTM)
62.880High62.075Low980.20KVolume62.430Open62.220Pre Close61.13MTurnover0.74%Turnover RatioLossP/E (Static)134.65MShares65.39552wk High6.05P/B8.27BFloat Cap49.12652wk Low0.54Dividend TTM133.08MShs Float65.394Historical High0.87%Div YieldTTM1.29%Amplitude7.992Historical Low62.363Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | KBR Inc : TD Cowen Raises Target Price to $70 From $62: TD Cowen Raises Target Price to $70 From $62
Express News | NYSE Order Imbalance 51886.0 Shares on Sell Side
Express News | KBR Announced That It Has Signed A Contract To Provide Its Green Ammonia Technology, K-GreeN, For Fortescue's Holmaneset Green Energy Project In Norway
Express News | KBR Inc: Signed a Contract to Provide Its Green Ammonia Technology, K-Green, for Fortescue's Holmaneset Green Energy Project in Norway
KBR Green Ammonia Technology Selected for Fortescue's Project in Norway
KBR (NYSE: KBR) announced today it has signed a contract to provide its green ammonia technology, K-GreeN, for Fortescue's Holmaneset green energy...
Take Care Before Diving Into The Deep End On KBR, Inc. (NYSE:KBR)
There wouldn't be many who think KBR, Inc.'s (NYSE:KBR) price-to-sales (or "P/S") ratio of 1.2x is worth a mention when the median P/S for the Professional Services industry in the United States is si
Comments
KBR's revenue growth could be seen as a positive sign, despite potential sacrifice of current earnings per share. Future earnings are crucial for shareholders. Despite slower share price gains, the business may continue to perform well.
Those Who Invested in KBR (NYSE:KBR) Five Years Ago Are up 238%Given the upward trend and increased efficiency in KBR's return on capital employed, it appears to show promise. Considering the outstanding shareholder returns over the last five years, it's advisable for investors to explore if these trends will continue.
Sizable insider selling at KBR creating investor caution. Lack of insider buying combined with substantial selling seen as red flag. 1.0% insider ownership doesn't fully dispel concerns.
ColumnsUS Top Gap Ups and Downs on 5/1: JPM, UBER, WFC, F and More
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
+9
11
ColumnsToday's pre-market stock movers: GOOS, TSLA, KSS, UAA and more
Gainers:
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
12
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg